Get access

Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia

Authors

  • E. Jolliffe,

    1. Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand
    Search for more papers by this author
  • K. Romeril

    Corresponding author
    1. Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand
    • Correspondence

      Ken Romeril, Consultant Haematologist, Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Private Bag 7902, Wellington 6242, New Zealand.

      Email: kenneth.romeril@ccdhb.org.nz

    Search for more papers by this author

  • Funding: None.
  • Conflict of interest: None.

Abstract

Autoimmune manifestations are a common occurrence with chronic lymphocytic leukaemia (CLL). We describe a case of CLL-associated immune thrombocytopenia (ITP) that had a loss of response to standard treatment for ITP. The thrombopoeitin receptor agonist, eltrombopag, was successfully used preoperatively to increase the platelet count to a safer level, in this instance to facilitate laparoscopic splenectomy.

Ancillary